Eldepryl Related Published Studies
Well-designed clinical trials related to Eldepryl (Selegiline)
Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. [2008.03]
A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. [2008]
Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. [2007.11]
Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. [2007.10.31]
Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. [2007.10]
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. [2007.09.25]
Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. [2007.09]
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. [2007.07.25]
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. [2007.04]
Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. [2007.01]
Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. [2007]
Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. [2006.12.01]
Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. [2006.12]
Selegiline slows the progression of the symptoms of Parkinson disease. [2006.04.25]
A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. [2005.12]
Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. [2005.02]
Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial. [2004.09]
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. [2004.04]
Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs. [2004.04]
A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. [2003.11]
A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. [2003.10]
Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. [2003.08]
Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study. [2003.07]
A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. [2003.02]
A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. [2003.01.15]
Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease. [2003]
[Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions] [2002.11]
Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. [2002.11]
Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. [2002.07]
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. [2002.05]
Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. [2001.04]
Selegiline treatment facilitates recovery after stroke. [2001]
[The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials] [2001]
Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease. [2000.11]
Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. [2000.01.11]
Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. [1999.09]
Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. [1999.05]
Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. [1999.03]
SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. [1999.03]
Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. [1998.08]
Mortality in people taking selegiline: observational study. [1998.07.25]
A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. [1998.07]
Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man. [1998.06]
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. [1998.04.18]
Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type. [1998.03]
Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. [1998.01]
Lack of adverse interactions between concomitantly administered selegiline and citalopram. [1997.10]
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. [1997.08]
Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. [1997.07]
Mortality associated with selegiline in Parkinson's disease. What do the available data mean? [1997.05]
A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity. [1997.05]
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. [1997.04.24]
Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study. [1997.04]
Selegiline in ADHD adults: plasma monoamines and monoamine metabolites. [1997.04]
Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. [1997.03]
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. [1997.03]
The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group. [1997.03]
Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease. [1997.03]
Bioavailability of two selegiline hydrochloride tablet products. [1996.11]
Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). [1996.10]
Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. [1996.10]
Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study. [1996.09]
Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. [1996]
Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline. [1996]
Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism. [1996]
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. [1995.12.16]
Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. [1995.10]
The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers. [1995.10]
Effects of selegiline (deprenyl) on cognition in early Parkinson's disease. [1995.08]
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. [1995.08]
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. [1995.05]
Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial. [1994.09]
High-dose selegiline in treatment-resistant older depressive patients. [1994.08]
An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. [1994.02]
Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. [1993.08]
A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. [1993.05.15]
Effects of selegiline dosing on motor fluctuations in Parkinson's disease. [1993.02]
A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. [1993.02]
Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. [1993]
Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group. [1993]
Selegiline in de novo parkinsonian patients: the Finnish study. [1993]
Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. [1993]
Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy. [1992.03]
Selegiline as initial treatment in de novo parkinsonian patients. [1992.02]
An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group. [1992]
Selegiline and cognitive function in Parkinson's disease. [1991.11]
Lisuride plus selegiline in the treatment of early Parkinson's disease. [1991.06]
Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). [1991]
Selegiline as a primary treatment of Parkinson's disease. [1991]
Optoelectronic movement analysis in Parkinson's disease: effect of selegiline on the disability in de novo parkinsonian patients--a pilot study. [1991]
Selegiline versus oxiracetam in patients with Alzheimer-type dementia. [1990.09]
Selegiline in the treatment of mild to moderate Alzheimer-type dementia. [1990.07]
Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. [1990.07]
Selegiline in Parkinson's disease. [1990.04]
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. [1989.08.04]
Selegiline as primary treatment in early phase Parkinson's disease--an interim report. [1989]
Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study. [1989]
Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease--an interim analysis. [1989]
Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. [1989]
Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial. [1987.09]
|
